289 related articles for article (PubMed ID: 33221464)
41. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
42. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Brodalumab.
Gambardella A; Licata G; De Rosa A; Pagliuca F; Calabrese G; Alfano R; Argenziano G
Dermatitis; 2021 Oct; 32(1S):e86-e88. PubMed ID: 33208631
[No Abstract] [Full Text] [Related]
43. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
Jensen JD; Huynh T; Cafardi J; Sami N
J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
[No Abstract] [Full Text] [Related]
44. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
[TBL] [Abstract][Full Text] [Related]
45. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
46. Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis.
Yosipovitch G; Dong Y; Burge R; Zhu B; Shrom D; Kimball AB
Acta Derm Venereol; 2019 Oct; 99(11):1031-1032. PubMed ID: 31290556
[No Abstract] [Full Text] [Related]
47. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
Teraki Y; Takahashi A; Inoue Y; Takamura S
Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
[No Abstract] [Full Text] [Related]
48. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
49. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
Azevedo A; Torres T
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment with ixekizumab of lower-limb linear psoriasis in a child.
Pourchot D; Mery-Bossard L; Petitjean B; Mahé E; Thomas-Beaulieu D
Ann Dermatol Venereol; 2022 Sep; 149(3):216-218. PubMed ID: 35282894
[No Abstract] [Full Text] [Related]
51. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
[No Abstract] [Full Text] [Related]
52. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
Liu Y; Zhang C; Li B; Yu C; Bai X; Xiao C; Wang L; Dang E; Yang L; Wang G
J Dermatol Sci; 2021 Feb; 101(2):84-92. PubMed ID: 33334656
[TBL] [Abstract][Full Text] [Related]
53. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
[No Abstract] [Full Text] [Related]
54. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
55. Is there room for another anti-interleukin-17 treatment in the crowded psoriasis therapeutic landscape?
Bergqvist C
Br J Dermatol; 2024 May; 190(6):e62-e63. PubMed ID: 37823402
[No Abstract] [Full Text] [Related]
56. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
57. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
58. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
59. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
60. The safety of brodalumab for the treatment of psoriasis.
Iznardo H; Puig L
Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
